Oxford Biomedica PLC Director Dealings / Market Share Purchase (5243N)
18 January 2019 - 9:51PM
UK Regulatory
TIDMOXB
RNS Number : 5243N
Oxford Biomedica PLC
18 January 2019
Director Dealings / Market Share Purchase
Oxford, UK - 18 January 2019: Oxford BioMedica plc ("Oxford
BioMedica" or "the Group") (LSE: OXB), a leading gene and cell
therapy group, today announces that Dr. Andrew Heath, Deputy
Chairman and Senior Independent Director of the Group, has
purchased 4,000 ordinary shares of 50p each ("Ordinary Shares") in
the Company on 17 January 2019 on the London Stock Exchange at a
price of 615.5p. Following this purchase Dr. Andrew Heath holds
40,000 shares representing 0.06% of the Company.
2,000 Ordinary Shares were purchased by Dr. Heath's wife (Eva
Lackner) and are therefore considered a beneficial holding of Dr.
Heath. The balance was purchased in his own name.
Stuart Paynter, Chief Financial Officer of the Group, has
purchased 1,622 ordinary shares of 50p each ("Ordinary Shares") in
the Company on 18 January 2019 on the London Stock Exchange at a
price of 612.8p. Following this purchase Stuart Paynter holds 3,375
shares representing 0.005% of the Company.
The below notification, made in accordance with the requirements
of the EU Market Abuse Regulation, gives further detail of the
number of Ordinary Shares purchased.
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Dr. Andrew Heath
2. Reason for the notification
a. Position/status Deputy Chairman and Senior Independent
Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford BioMedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford BioMedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP6.16 2,000
e. Aggregated information 2,000
* Aggregated volume GBP6.155038
GBP12,310.08
* Price
* Aggregated total
f. Date of the transaction 2019-01-17
g. Place of the transaction London Stock Exchange, Main Market (XLON)
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Eva Lackner
2. Reason for the notification
a. Position/status Person closely associated with Dr. Andrew
Heath, Deputy Chairman and Senior Independent
Director
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford BioMedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford BioMedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP6.16 2,000
e. Aggregated information 2,000
* Aggregated volume GBP6.155038
GBP12,310.08
* Price
* Aggregated total
f. Date of the transaction 2019-01-17
g. Place of the transaction London Stock Exchange, Main Market (XLON)
1. Details of the person discharging material responsibilities/person
closely associated
a. Name Stuart Paynter
2. Reason for the notification
a. Position/status Chief Financial Officer
b. Initial notification Initial notification
/amendment
3. Details of the issuer, emission allowance, market
participant, auction platform, auctioneer or auction
monitor
a. Name Oxford BioMedica plc
b. Legal Entity Identifier 213800S1GVQNXQ15K851
4. Details of the transaction(s); section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
a. Description of Oxford BioMedica plc Ordinary Shares
the financial of 50p each
instrument, type GB00BDFBVT43
of instrument
identification
code
b. Nature of the Purchase of ordinary shares
transaction
c. Currency GBP - British Pound
d. Price(s) and volume(s) Price(s) Volume(s)
GBP6.13 1,622
e. Aggregated information 1,622
* Aggregated volume GBP6.1277218
GBP9,939.16
* Price
* Aggregated total
f. Date of the transaction 2019-01-18
g. Place of the transaction London Stock Exchange, Main Market (XLON)
The issued share capital of the Group is 66,103,528 ordinary 50p
shares.
-Ends-
For further information, please contact:
Oxford BioMedica plc: Tel: +44 (0)1865 783 000
Stuart Paynter, Company Secretary
Notes for editors
About Oxford BioMedica
Oxford BioMedica (LSE:OXB) is a leading gene and cell therapy
group focused on developing life changing treatments for serious
diseases. Oxford BioMedica and its subsidiaries (the "Group") have
built a sector leading lentiviral vector delivery platform
(LentiVector(R) ), which the Group leverages to develop in vivo and
ex vivo products both in-house and with partners. The Group has
created a valuable proprietary portfolio of gene and cell therapy
product candidates in the areas of oncology, ophthalmology and CNS
disorders. The Group has also entered into a number of
partnerships, including with Novartis, Bioverativ, Sanofi, Axovant,
Orchard Therapeutics, Boehringer Ingelheim, the UK Cystic Fibrosis
Gene Therapy Consortium and Imperial Innovations, GC LabCell and
Immune Design, through which it has long-term economic interests in
other potential gene and cell therapy products. Oxford BioMedica is
based across several locations in Oxfordshire, UK and employs more
than 360 people. Further information is available at
www.oxb.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHSFUFSAFUSELF
(END) Dow Jones Newswires
January 18, 2019 05:51 ET (10:51 GMT)
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From Apr 2024 to May 2024
Oxford Biomedica (LSE:OXB)
Historical Stock Chart
From May 2023 to May 2024